

Hernia: Covidien's Biologic Mesh Product Hits a Wall

Mass Device

Covidien CFO Charles Dockendorff says there's not much room for growth in biologic tissue mesh for hernia repair, a product the company acquired in 2008.



[Covidien's](#) [1] (NYSE:[COV](#) [2]) biologic hernia mesh product has hit a "brick wall," according to CFO Charles Dockendorff, but does that mean the company is looking to move on from the product it dropped more than \$80 million to acquire?

Dockendorff, responding to a question from [CitiGroup analyst Matthew Dodds](#) [3] at the investment bank's recent investor's conference, sounded downbeat about the fate of the product compared to the company's synthetic mesh.

Source URL (retrieved on 01/30/2015 - 8:20pm):

<http://www.mdtmag.com/news/2013/03/hernia-covidien-biologic-mesh-product-hits-wall>

Links:

[1] <http://www.massdevice.com/company/covidien>

[2] <http://www.google.com/finance?q=cov>

[3] <http://www.covidien.com/hernia/us/biologics>